The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Impact of COVID-19 on MPNs patients
Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ, presents the preliminary data from a survey-based study investigating the effects of the COVID-19 pandemic on the lifestyle and quality of life of patients with myeloproliferative neoplasms (MPNs). Although the proportion of patients that contracted COVID-19 was very low, patients reported impacts on their daily life including stress, fatigue, and clinical care. Further studies are warranted to explore the long-term effects of the pandemic on patients with MPN. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
